Nafamostat intravenous (Lowell Therapeutics)

N/A

Report date: 2025/10/27 17:55:53

Base Information

Drug NameNafamostat intravenous (Lowell Therapeutics)
Drug Alias NameLTX-608
ClassificationSmall molecules
Mechanisms of ActionSerine protease inhibitors
TargetsSerine protease
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Disseminated Intravascular CoagulationRespiratory Distress Syndrome, Adult +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLowell Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTalphera Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Disseminated Intravascular CoagulationRespiratory Distress Syndrome, Adult +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A